Proapoptotic and immunomodulatory effects of SYK inhibitor entospletinib in combination with obinutuzumab in patients with chronic lymphocytic leukaemia.

Lam, Vi; Best, Scott; Kittai, Adam; Orand, Kirsten; Spurgeon, Stephen E; Liu, Tingting; Danilov, Alexey V

Lam, Vi; Best, Scott; Kittai, Adam; Orand, Kirsten; Spurgeon, Stephen E; Liu, Tingting; Danilov, Alexey V.

Afiliação

Lam V; City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
Best S; Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Kittai A; Ohio State University, Columbus, OH, USA.
Orand K; City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
Spurgeon SE; Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Liu T; City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
Danilov AV; City of Hope Comprehensive Cancer Center, Duarte, CA, USA.

Br J Clin Pharmacol ; 88(2): 836-841, 2022 02.

Article em En | MEDLINE | ID: mdl-34196037

Assuntos

Leucemia Linfocítica Crônica de Células B; Anticorpos Monoclonais Humanizados; Humanos; Indazóis; Leucemia Linfocítica Crônica de Células B/tratamento farmacológico; Recidiva Local de Neoplasia; Pirazinas; Receptores de Antígenos de Linfócitos B/uso terapêutico; Quinase Syk/antagonistas & inibidores; Quinase Syk/uso terapêutico

Palavras-chave

MCL1; PD-1; chronic lymphocytic leukaemia; spleen tyrosine kinase

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Leucemia Linfocítica Crônica de Células B Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google